Dapagliflozin helps preserve kidney function in peritoneal dialysis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of dapagliflozin on preserving residual renal function (RRF) in patients undergoing peritoneal dialysis (PD). It aims to determine whether this sodium-glucose co-transporter-2 (SGLT2) inhibitor can protect RRF and improve cardiac health over a 24-week treatment period. The study will enroll patients with a PD duration of 1 to 3 months and will monitor various health parameters to assess the drug's efficacy. The research is motivated by previous findings that SGLT2 inhibitors may reduce renal injury and improve outcomes in chronic kidney disease patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with PD duration between 1 month and 3 months.
* Patients aged between 18 and 75 years.
* Voluntary signing of informed consent.
* Stable use of a maximum tolerated dose of RAAS inhibitors for one month if hypertension is present.
* Daily urine output ≥ 400ml/day.
* Stable PD prescription for one month.

Exclusion Criteria:

* Pregnant and lactating women.
* Patients with type 1 diabetes mellitus.
* Patients with type 2 diabetes mellitus who have experienced diabetic ketoacidosis in the past.
* Patients with chronic liver disease, including non-alcoholic fatty liver disease, cirrhosis, ALT \> 120 IU/L, and other clinically confirmed severe liver diseases.
* Patients with more than 2 episodes of urinary tract infection in the past six months.
* Patients with severe allergic reactions (rash or angioedema) to Dapagliflozin.
* Patients using the following medications: rifampicin, phenytoin.
* Patients with malignant tumors.
* Patients who developed peritonitis within one month.
* Patients undergoing combined hemodialysis treatment.
* Patients with a willingness for kidney transplantation within six months.
* Patients with a history of pancreatitis or pancreatic transplantation.
* Patients who experienced acute coronary syndrome or cerebrovascular events within one month.
* Hemoglobin level less than 90g/L.

Where it's running

• Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospita
  Chengdu, Sichuan, China Recruiting

Study contacts

• Principal investigator: Jin Chen, MD — Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital
• Study coordinator: Jin Chen, MD
• Email: jessicakxcj@uestc.edu.cn
• Phone: 0086-28-87393195

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating the safety and mechanisms of SGLT2 inhibitors in patients on peritoneal dialysis

  This study is testing if a diabetes medication called empagliflozin is safe and helpful for people on peritoneal dialysis who still have some kidney function, to see if it can protect their heart and kidneys.

  Recruiting Phase 3 University Health Network, Toronto · Toronto, Ontario · NCT05715814

• Dapagliflozin to lower albuminuria in adolescents with early chronic kidney disease

  We will test whether a once-daily 10 mg dapagliflozin pill lowers urine albumin in 14–18-year-olds from Aguascalientes who have early chronic kidney disease and persistent microalbuminuria.

  Recruiting Phase 4 Centenario Hospital Miguel Hidalgo · Aguascalientes, Aguascalientes · NCT07405216

• Using empagliflozin to improve kidney function in new peritoneal dialysis patients

  This study tests if adding a diabetes medication called empagliflozin can help new peritoneal dialysis patients keep their kidney function and improve their overall health.

  Recruiting Phase 2 Chinese University of Hong Kong · Hong Kong · NCT06483074

• International Pediatric Peritoneal Biobank

  This study is collecting tissue samples from children on peritoneal dialysis to see how the treatment affects their bodies and health outcomes.

  Recruiting at 17 sites Heidelberg University · Birmingham, Alabama and 25 other locations · NCT01893710

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.